BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Methylprednisolone readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Methylprednisolone\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07208799-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT07208799)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Comparison of Submucosal 
 Dexamethasone and Methylprednisolone in Postoperative Sequelae of Parasymp
 hsis Fractures\nEstimated primary completion: 30 November 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/methylprednisolone#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07208799
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06670521-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT06670521)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Corticosteroids for Post-
 Extubation Dysphagia\nEstimated primary completion: 30 November 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/methylprednisolone#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06670521
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06924983-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT06924983)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Neuroendoscopic Hematoma 
 Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatm
 ent of Basal Ganglia Intracerebral Hemorrhage at the Early Stage\nEstimate
 d primary completion: 30 November 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06924983
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06921616-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT06921616)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Neuroendoscopic Hematoma 
 Evacuation Combined With Methylprednisolone Sodium Succinate in the Treatm
 ent of Lobar Intracerebral Hemorrhage at the Early Stage.\nEstimated prima
 ry completion: 30 November 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/methylprednisolone#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06921616
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02283996-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT02283996)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Adhesive Capsulitis: Pros
 pective Analysis of Efficacy and Financial Impact for Use of Physical Ther
 apy in Treatment\nEstimated primary completion: December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/methylprednisolone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT02283996
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04216524-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT04216524)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Venetoclax\, SL-401\, and
  Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neo
 plasm\nEstimated primary completion: 31 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04216524
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05058287-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT05058287)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: Lumbar Steroid Use in Pat
 ients Undergoing Posterior Lumbar Decompression\nEstimated primary complet
 ion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/methylprednisolone#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05058287
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07101445-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT07101445)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Evaluating Premedication 
 Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of
  Systemic and Injection Site Reactions to Motixafortide in Patients With M
 ultiple Myeloma Undergoing Stem Cell Mobilization\, PARADE Trial\nEstimate
 d primary completion: 31 December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07101445
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393503-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT07393503)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Musculoskeletal Outcomes 
 Using Tylenol/Ibuprofen vs. Oral Steroids in New Injuries\nEstimated prima
 ry completion: January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/methylprednisolone#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07393503
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07328906-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Methylprednisolone: Phase na readout est. (NCT07328906)
DESCRIPTION:Methylprednisolone\, phase na.\nStudy: Steroid Treatment to Pre
 vent Thoracic Endovascular Aortic Repair Postimplantation Syndrome\nEstima
 ted primary completion: January 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/methylprednisolone#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07328906
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03579875-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT03579875)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Alpha/Beta TCD HCT in Pat
 ients With Inherited BMF Disorders\nEstimated primary completion: 1 Januar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/methylprednis
 olone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03579875
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07054801-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT07054801)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: IA Lidocaine and Methylpr
 ednisolone for Headache Associated With Subarachnoid Hemorrhage\nEstimated
  primary completion: 1 January 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/methylprednisolone#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07054801
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04411654-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Methylprednisolone: Phase 1/2 readout est. (NCT04411654)
DESCRIPTION:Methylprednisolone\, phase 1/2.\nStudy: Phase 1/2 Clinical Tria
 l of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)\nEstimated pri
 mary completion: February 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/methylprednisolone#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04411654
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05734625-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT05734625)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Efficacy of Nerve Blocks 
 for Episodic Migraine\nEstimated primary completion: February 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/methylprednisolone#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05734625
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07394894-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT07394894)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Local Percutaneous Pulsed
  Radiofrequency Ablation Versus Ultrasound Guided Steroids Injection in Ma
 nagement of Pain in Cases of Chronic Planter Fascitis\, Randomised Double 
 Blinded Study\nEstimated primary completion: March 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/methylprednisolone#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07394894
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06922669-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Methylprednisolone: Phase na readout est. (NCT06922669)
DESCRIPTION:Methylprednisolone\, phase na.\nStudy: Glucocorticoids for Acut
 e Drug Induced Liver Injury With Hyperbilirubinemia\nEstimated primary com
 pletion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/methylprednisolone#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06922669
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06225310-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Methylprednisolone: Phase 1 readout est. (NCT06225310)
DESCRIPTION:Methylprednisolone\, phase 1.\nStudy: A Trial of Selinexor\, Ru
 xolitinib and Methylprednisolone\nEstimated primary completion: 1 April 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/methylprednisolon
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 225310
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05303792-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT05303792)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Comparing Inotuzumab Comb
 ined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemothera
 py Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic
  Leukemia\nEstimated primary completion: 1 April 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05303792
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06356571-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT06356571)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: A Study to Investigate Su
 bcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexametha
 sone in Adult Participants With Relapsed and/or Refractory Multiple Myelom
 a\nEstimated primary completion: 1 April 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06356571
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05097976-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT05097976)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Medrol Dosepak for Outpat
 ient Total Knee Arthroplasty\nEstimated primary completion: 30 May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/methylprednisolone#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0509797
 6
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07788456-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT07788456)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Multi-target Drugs Sequen
 tial Combination Therapy in Adults Patients With Newly Diagnosed Primary I
 mmune Thrombocytopenia\nEstimated primary completion: 30 May 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/methylprednisolone#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07788456
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780202-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT06780202)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Assessment of Medrol Dose
 pak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients\nEsti
 mated primary completion: June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/methylprednisolone#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06780202
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06936566-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT06936566)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: MAGIC Ruxolitinib for aGV
 HD\nEstimated primary completion: 1 June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06936566
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06266221-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT06266221)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: Severe Erythema Multiform
 e - CORTICO\nEstimated primary completion: 1 June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/methylprednisolone#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06266221
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07152600-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT07152600)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: Adaptive RCT of Corticost
 eroids for Severe Adenovirus Pneumonia in Adults\nEstimated primary comple
 tion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/m
 ethylprednisolone#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07152600
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762105-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Methylprednisolone: Phase 1 readout est. (NCT07762105)
DESCRIPTION:Methylprednisolone\, phase 1.\nStudy: Study of Atorvastatin and
  Its Effects in Clinical and Radiological Aspects in Patients With Moderat
 e-to-Severe Thyroid Eye Disease\nEstimated primary completion: 30 July 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/methylprednisolone
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 62105
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04151082-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Methylprednisolone: Phase 1/2 readout est. (NCT04151082)
DESCRIPTION:Methylprednisolone\, phase 1/2.\nStudy: High Dose Steroid Thera
 py (Prednisone or Methylprednisolone) for the Improvement of Symptoms of L
 ate Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer 
 Survivors\nEstimated primary completion: 31 July 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04151082
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05279092-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT05279092)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Yale Steroid Enhanced Ver
 sus Exparel Nerveblock TKA RCT Study\nEstimated primary completion: Septem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methylpredn
 isolone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05279092
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05736549-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT05736549)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Yale Steroid Enhanced Ver
 sus Exparel Nerveblock TKA Part 2\nEstimated primary completion: September
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/methylpredniso
 lone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05736549
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04224558-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Methylprednisolone: Phase 1/2 readout est. (NCT04224558)
DESCRIPTION:Methylprednisolone\, phase 1/2\, Crohn's Disease.\nStudy: Stem 
 Cell Transplantation in Crohn's Disease\nEstimated primary completion: 30 
 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methy
 lprednisolone#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04224558
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185633-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT07185633)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Study of Gecacitinib-cort
 icosteroid as First-line Therapy for Grade II-IV Acute Graft Versus Host D
 isease\nEstimated primary completion: 1 October 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07185633
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287397-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Methylprednisolone: Phase 1/2 readout est. (NCT07287397)
DESCRIPTION:Methylprednisolone\, phase 1/2.\nStudy: Study is to Assess the 
 Safety and Tolerability of VTx-002 in Participants With ALS\nEstimated pri
 mary completion: 15 October 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/methylprednisolone#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07287397
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052929-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Methylprednisolone: Phase 1/2 readout est. (NCT07052929)
DESCRIPTION:Methylprednisolone\, phase 1/2.\nStudy: Study of ASP2957 in Mal
 e Participants With X-linked Myotubular Myopathy Who Need Ventilators\nEst
 imated primary completion: 31 October 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07052929
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05867329-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT05867329)
DESCRIPTION:Methylprednisolone\, phase 4\, Ulcerative Colitis.\nStudy: Feas
 ibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for 
 Acute Severe Ulcerative Colitis\nEstimated primary completion: November 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/methylprednisolon
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 867329
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07255248-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT07255248)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Hoffa's Fat Pad Impingeme
 nt (HFPI)\nEstimated primary completion: 1 November 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/methylprednisolone#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07255248
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509749-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT07509749)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Novel Therapies for Sever
 e Acute GVHD (Graft-versus-host Disease)\nEstimated primary completion: 30
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methy
 lprednisolone#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07509749
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07516522-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT07516522)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Intra-arterial Methylpred
 nisolone After Endovascular Thrombectomy\nEstimated primary completion: 31
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methy
 lprednisolone#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07516522
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07902609-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT07902609)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Sequential Daratumumab Fo
 llowed by Telitacicept for the Treatment of ABMR After Kidney Transplantat
 ion-A Phase IIa Clinical Trial\nEstimated primary completion: 31 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/methylprednisol
 one#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07902609
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07141303-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT07141303)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: Intra-arterial Methylpred
 nisolone After Successful Endovascular Thrombectomy Anterior Circulation L
 arge Vessel Occlusion\nEstimated primary completion: 31 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/methylprednisolone#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07141303
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07650396-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT07650396)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: The ASPIRE Trial: Achille
 S tendinoPathy Treated With cortIcosteRoid injEctions\nEstimated primary c
 ompletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/methylprednisolone#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07650396
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05925309-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Methylprednisolone: Phase na readout est. (NCT05925309)
DESCRIPTION:Methylprednisolone\, phase na.\nStudy: Preventive Effect of Pro
 phylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostom
 y\nEstimated primary completion: 31 December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05925309
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04936854-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT04936854)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Sirolimus vs Corticostero
 ids in Treatment of Thyroid Eye Disease\nEstimated primary completion: Jan
 uary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methylpred
 nisolone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04936854
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07804199-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Methylprednisolone: Phase na readout est. (NCT07804199)
DESCRIPTION:Methylprednisolone\, phase na.\nStudy: taVNS in Veterans With K
 nee OA (AVAHCS)\nEstimated primary completion: 1 January 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/methylprednisolone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07804199
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06676579-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT06676579)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Avacopan in Crescentic Im
 munoglobulin A Nephropathy (IgAN)\nEstimated primary completion: March 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/methylprednisolone
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066
 76579
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05150704-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT05150704)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: MYTHS - MYocarditis THera
 py With Steroids\nEstimated primary completion: March 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/methylprednisolone#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05150704
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07763210-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT07763210)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Intrathecal Cytarabine an
 d Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing C
 AR T Therapy for Non Hodgkin Lymphoma\nEstimated primary completion: 1 Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/methylpredni
 solone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07763210
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07525466-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Methylprednisolone: Phase 1/2 readout est. (NCT07525466)
DESCRIPTION:Methylprednisolone\, phase 1/2.\nStudy: Combination of Mitoxant
 rone Liposome and Etoposide\, Dexamethasone\, Pegaspargase and Golidocitin
 ib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocyt
 ic Lymphohistiocytosis (NKTCL-HLH)\nEstimated primary completion: 31 March
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/methylpredniso
 lone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07525466
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07371572-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT07371572)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: The Efficacy and Safety o
 f Intramuscular Methylprednisolone in Patients With Hand OsteoArthritis\nE
 stimated primary completion: April 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07371572
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511582-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20280401
DTEND;VALUE=DATE:20280402
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT07511582)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Corticosteroids in Hyperi
 nflammatory Phenotype of Critical Illness\nEstimated primary completion: 1
  April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methylpr
 ednisolone#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07511582
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06373211-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT06373211)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Early Immunotherapy with 
 Intravenous Immunoglobulin\, Cyclophosphamide and Methylprednisolone in Pa
 tients with Anti-Hu-associated Paraneoplastic Sensory Neuronopathy\nEstima
 ted primary completion: June 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/methylprednisolone#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06373211
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07542288-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Methylprednisolone: Phase 2/3 readout est. (NCT07542288)
DESCRIPTION:Methylprednisolone\, phase 2/3.\nStudy: Comparison of the Thera
 peutic Effects of Methylprednisolone and Dexamethasone on Peritumoral Edem
 a During Radiotherapy for Brain Metastases:\nEstimated primary completion:
  30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methyl
 prednisolone#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07542288
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06081101-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Methylprednisolone: Phase 1 readout est. (NCT06081101)
DESCRIPTION:Methylprednisolone\, phase 1.\nStudy: Ketorolac Versus Corticos
 teroid Injections for Sacroiliac Joint Pain\nEstimated primary completion:
  July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methylpre
 dnisolone#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06081101
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07455396-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20280814
DTEND;VALUE=DATE:20280815
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT07455396)
DESCRIPTION:Methylprednisolone\, phase 2\, Asthma.\nStudy: Pediatric Asthma
  Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Ver
 sus Methylprednisolone for Pediatric Critical Asthma\nEstimated primary co
 mpletion: 14 August 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/methylprednisolone#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07455396
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06522100-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20280816
DTEND;VALUE=DATE:20280817
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT06522100)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: Corticoid Therapy in Acut
 e Myocarditis\nEstimated primary completion: 16 August 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/methylprednisolone#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06522100
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07357935-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Methylprednisolone: Phase 1/2 readout est. (NCT07357935)
DESCRIPTION:Methylprednisolone\, phase 1/2.\nStudy: Early Inflammatory-Immu
 ne Stratification and Precision Glucocorticoid Intervention in Acute Respi
 ratory Failure Induced by Community-Acquired Pneumonia\nEstimated primary 
 completion: 1 September 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/methylprednisolone#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07357935
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06968507-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20280910
DTEND;VALUE=DATE:20280911
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT06968507)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Comparison of the Effecti
 veness of Oral and Intratympanic Corticosteroid Treatments in Patients Dia
 gnosed With Sudden Sensorineural Hearing Loss\nEstimated primary completio
 n: 10 September 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /methylprednisolone#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06968507
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03219359-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT03219359)
DESCRIPTION:Methylprednisolone\, phase 2\, Crohn's Disease.\nStudy: Autolog
 ous Stem Cell Transplant for Crohn's Disease\nEstimated primary completion
 : October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methy
 lprednisolone#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03219359
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07568496-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Methylprednisolone: Phase na readout est. (NCT07568496)
DESCRIPTION:Methylprednisolone\, phase na.\nStudy: Greater Occipital Nerve 
 Block for Migraine With Medication Overuse Headache\nEstimated primary com
 pletion: 1 November 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/methylprednisolone#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07568496
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06730308-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20281119
DTEND;VALUE=DATE:20281120
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT06730308)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Glucocorticoids Combined 
 With Concurrent Chemoradiotherapy for Unresectable Thymoma\nEstimated prim
 ary completion: 19 November 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/methylprednisolone#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06730308
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352865-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT07352865)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: Adaptive RCT of Corticost
 eroids for Severe Chlamydia Psittaci Pneumonia in Adults\nEstimated primar
 y completion: 30 November 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/methylprednisolone#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07352865
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07351500-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT07351500)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: Adaptive RCT of Corticost
 eroids for Severe Influenza Pneumonia in Adults\nEstimated primary complet
 ion: 30 November 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/methylprednisolone#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07351500
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175649-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Methylprednisolone: Phase na readout est. (NCT07175649)
DESCRIPTION:Methylprednisolone\, phase na.\nStudy: Methylprednisolone Sodiu
 m Succinate With Endovascular ThRombectomy for Large Ischemic STroke\nEsti
 mated primary completion: December 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07175649
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07554885-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Methylprednisolone: Phase na readout est. (NCT07554885)
DESCRIPTION:Methylprednisolone\, phase na.\nStudy: Nutritional + Usual Cort
 icosteroids Randomized Trial for Immune-Related pneumoniA - Therapeutic Ut
 ilization Evaluation\nEstimated primary completion: December 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/methylprednisolone#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07554885
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07353749-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT07353749)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Efficacy and Safety of Me
 thylprednisolone After Flow-Diverter Stent Implantation in Unruptured Intr
 acranial Aneurysms\nEstimated primary completion: 1 December 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/methylprednisolone#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07353749
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02784210-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT02784210)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Effect of Corticosteroids
  on Inflammation at the Edge of Acute Multiple Sclerosis Plaques\nEstimate
 d primary completion: 31 December 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT02784210
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06317662-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT06317662)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Testing the Addition of t
 he Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinat
 umomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnose
 d KMT2A-rearranged or KMT2A-non-rearranged Leukemia\nEstimated primary com
 pletion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/methylprednisolone#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06317662
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07902843-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT07902843)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Methylprednisolone Taper 
 is an Effective Addition to Multimodal Pain Regimens After Rotator Cuff Re
 pair\nEstimated primary completion: 31 December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07902843
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06870448-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT06870448)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: Methylprednisolone With E
 ndovascular Thrombectomy for Large Ischemic Stroke\nEstimated primary comp
 letion: January 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /methylprednisolone#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06870448
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03661645-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT03661645)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Post-operative Methylpred
 nisolone Taper Course for Orthopedic Surgery\nEstimated primary completion
 : January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methy
 lprednisolone#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03661645
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05139849-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT05139849)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: VAsopressin and STeroids 
 in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial\
 nEstimated primary completion: 31 January 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05139849
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07180277-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT07180277)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Methylprednisolone for Mo
 derate to Severe Traumatic Brain Injury\nEstimated primary completion: 31 
 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methylp
 rednisolone#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07180277
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06471556-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT06471556)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Efficacy of Methylprednis
 olone Pulses in Neuroendocrine Celles Hyperplasia of Infancy : An Early Ph
 ase Study\nEstimated primary completion: 28 February 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/methylprednisolone#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06471556
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507643-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20290327
DTEND;VALUE=DATE:20290328
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT07507643)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: A Study of Methylpredniso
 lone in People Having Liver Surgery\nEstimated primary completion: 27 Marc
 h 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/methylprednis
 olone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07507643
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07803978-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Methylprednisolone: Phase 1 readout est. (NCT07803978)
DESCRIPTION:Methylprednisolone\, phase 1.\nStudy: Prospective Randomized Co
 ntrolled Study: Amimaitosai Injection Combined With Corticosteroids for Ga
 strointestinal aGVHD\nEstimated primary completion: 1 May 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/methylprednisolone#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07803978
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01624805-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT01624805)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Methylprednisolone\, Hors
 e Anti-Thymocyte Globulin\, Cyclosporine\, Filgrastim\, and/or Pegfilgrast
 im or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia o
 r Low or Intermediate-Risk Myelodysplastic Syndrome\nEstimated primary com
 pletion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/methylprednisolone#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT01624805
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06717347-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20290702
DTEND;VALUE=DATE:20290703
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT06717347)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: A Study to Evaluate Zilov
 ertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide
 \, Doxorubicin\, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophospha
 mide\, Doxorubicin\, Vincristine\, and Prednisone (R-CHOP) in Participants
  With Previously Untreated DLBCL (MK-2140-010)\nEstimated primary completi
 on: 2 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/meth
 ylprednisolone#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06717347
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06040255-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT06040255)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Focal Cerebral Arteriopat
 hy Steroid Trial\nEstimated primary completion: 31 July 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/methylprednisolone#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06040255
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07412470-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20290815
DTEND;VALUE=DATE:20290816
SUMMARY:Methylprednisolone: Phase 2/3 readout est. (NCT07412470)
DESCRIPTION:Methylprednisolone\, phase 2/3.\nStudy: A Study to Investigate 
 the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoi
 ng Kidney Transplantation\nEstimated primary completion: 15 August 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/methylprednisolone#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0741247
 0
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07703098-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT07703098)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Hydrocortisone Versus Met
 hylprednisolone for the Treatment of Glucocorticoid-Induced Adrenal Insuff
 iciency\nEstimated primary completion: 1 September 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/methylprednisolone#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07703098
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04408625-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Methylprednisolone: Phase 1/2 readout est. (NCT04408625)
DESCRIPTION:Methylprednisolone\, phase 1/2.\nStudy: Phase 1/2 Clinical Tria
 l of LY3884963 in Patients With Frontotemporal Dementia With Progranulin M
 utations (FTD-GRN)\nEstimated primary completion: 30 November 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/methylprednisolone#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04408625
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762170-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT07762170)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Success Rates and Safety 
 of Steroid Injections in Managing Spinal and Sacro-Iliac Pain (CORTisone I
 njection Spine Study)\nEstimated primary completion: December 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/methylprednisolone#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07762170
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03952637-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Methylprednisolone: Phase 1/2 readout est. (NCT03952637)
DESCRIPTION:Methylprednisolone\, phase 1/2.\nStudy: A Phase 1/2 Study of In
 travenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactos
 idase in Type I and Type II GM1 Gangliosidosis\nEstimated primary completi
 on: 1 January 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/m
 ethylprednisolone#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03952637
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06474273-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT06474273)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: A Multicenter Randomized 
 Controlled Trial to Treat Acute T Cell Mediated Rejection in Kidney and Ki
 dney-Pancreas Transplant Recipients\nEstimated primary completion: June 20
 30. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/methylprednisolon
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 474273
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04305145-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Methylprednisolone: Phase 2 readout est. (NCT04305145)
DESCRIPTION:Methylprednisolone\, phase 2.\nStudy: Infliximab for Treatment 
 of Immune Checkpoint Inhibitor Colitis\nEstimated primary completion: 30 J
 une 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methylpredn
 isolone#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04305145
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892210-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20300801
DTEND;VALUE=DATE:20300802
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT06892210)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Comparing Hydrocortisone 
 and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary D
 isease (AECOPD)\nEstimated primary completion: 1 August 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/methylprednisolone#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06892210
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892197-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20300801
DTEND;VALUE=DATE:20300802
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT06892197)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Comparing Hydrocortisone 
 and Prednisolone for Community Acquired Pneumonia (CAP)\nEstimated primary
  completion: 1 August 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/methylprednisolone#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06892197
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07158476-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT07158476)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Efficacy of Methylprednis
 olone for Pain Control After ACL Repair\nEstimated primary completion: Sep
 tember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/methylpr
 ednisolone#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07158476
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04270409-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20301014
DTEND;VALUE=DATE:20301015
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT04270409)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: Isatuximab in Combination
  With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myel
 oma\nEstimated primary completion: 14 October 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04270409
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07478003-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20310420
DTEND;VALUE=DATE:20310421
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT07478003)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: Prehospital Pulse-dose Gl
 ucocorticoid in Patients With ST-segment Elevation Myocardial Infarction 2
  - The PULSE-MI 2 Trial\nEstimated primary completion: 20 April 2031. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/methylprednisolone#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07478003
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605923-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Methylprednisolone: Phase 4 readout est. (NCT07605923)
DESCRIPTION:Methylprednisolone\, phase 4.\nStudy: Methylprednisolone Additi
 on to Multimodal Pain Regimens After Anterior Cruciate Ligament Reconstruc
 tion\nEstimated primary completion: August 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07605923
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04127578-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Methylprednisolone: Phase 1/2 readout est. (NCT04127578)
DESCRIPTION:Methylprednisolone\, phase 1/2.\nStudy: Phase 1/2a Clinical Tri
 al of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least
  One GBA1 Mutation (PROPEL)\nEstimated primary completion: 31 August 2031.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/methylprednisolone#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04127
 578
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04702256-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Methylprednisolone: Phase 3 readout est. (NCT04702256)
DESCRIPTION:Methylprednisolone\, phase 3.\nStudy: Induction Therapy for Lup
 us Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticost
 eroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF\nEstim
 ated primary completion: December 2031. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04702256
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07270549-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Methylprednisolone: Phase 1/2 readout est. (NCT07270549)
DESCRIPTION:Methylprednisolone\, phase 1/2.\nStudy: Gene Replacement Therap
 y for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Synd
 rome\nEstimated primary completion: 31 December 2032. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07270549
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07072585-4661@assetmemo.bio
DTSTAMP:20261121T005630Z
DTSTART;VALUE=DATE:20350901
DTEND;VALUE=DATE:20350902
SUMMARY:Methylprednisolone: Phase 2/3 readout est. (NCT07072585)
DESCRIPTION:Methylprednisolone\, phase 2/3.\nStudy: Testing the Addition of
  Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-
 Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-L
 L)\nEstimated primary completion: 1 September 2035. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/methylprednisolone#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07072585
URL:https://assetmemo.bio/drug/methylprednisolone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
